EGFR and non-small cell lung carcinoma: For instance, Navitoclax,265 a clinical drug developed based on ABT-263, has shown promising results in combating drug resistance in DTP cells associated with drug-resistant lymphoma,275 EGFR-resistant NSCLC,276, and recurrent epithelial ovarian cancer.277 This serves as sufficient evidence to demonstrate the effectiveness of anti-DTP therapy in treating drug-resistant tumors.